{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    10,
    12,
    16,
    21,
    31,
    36,
    41,
    45,
    48
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_4",
        "affectedSection": "Section 3.5, 5.3.1.1, 5.4.1, 5.7, 6.1.6, 9.2, 9.3",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added COVID-19 pandemic benefits/risks evaluation and updated study procedures including local labs and drug shipment."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.1, 5.3.1.1, Appendix F",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduced off-site phone visit options for subjects on stable long-term monotherapy."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.1.1, Synopsis",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified tumor assessment schedule and central review requirements following primary analysis."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.5, 8.1.8",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Discontinuation of IDMC reviews following primary analysis."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_4",
        "affectedSection": "Section 6.1.5",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added reporting requirements for secondary primary malignancies and myeloid disorders."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_4",
        "reasonText": "To allow for procedure modification in response to the COVID-19 pandemic and confirm benefit-risk profile.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_4",
        "reasonText": "Primary analysis was completed on 03 June 2019, allowing for unblinding of the sponsor and reduction of central monitoring requirements.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_4",
        "reasonText": "To limit cumulative radiation exposure for patients with long-term disease control.",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_4",
        "reasonText": "To align with the most recent version of the Statistical Analysis Plan.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.1.1",
        "beforeText": "every 9 weeks from C1D-2",
        "afterText": "every 12 weeks from last scan (not to exceed 24 weeks per investigator discretion)",
        "summary": "Updated tumor assessment schedule for subjects with durable disease control."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.3",
        "beforeText": "Secondary endpoint",
        "afterText": "Tertiary endpoint",
        "summary": "Changed status of Duration of Response (DOR) endpoint."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_4",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.5",
        "afterText": "reporting of myelodysplastic syndrome, acute myeloid leukemia, or any secondary primary malignancy",
        "summary": "Added specific adverse events of special interest reporting requirements."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_4",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "Global",
        "beforeText": "Blinded/Unblinded TA MD and study teams",
        "afterText": "AbbVie TA MD / Sponsor",
        "summary": "Removed references to separate blinded/unblinded sponsor teams following primary analysis."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Appendix E",
        "beforeText": "Standard Post Treatment Phase procedures",
        "afterText": "Modified schedule of assessments for safety monitoring and tumor assessment only",
        "summary": "Simplified procedures for subjects who discontinue therapy without progressive disease."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}